1991 Volume 5 Issue 2 Pages 182-188
An 11-year-old boy with severe aplastic anemia was treated by allogeneic bone marrow transplantation (BMT). The transplant donor was his 3-year-old sister, who was HLA-identical, MLC-negative, and ABO mismatched. Beginning the day after BMT, the patient received an intravenous injection of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) at a dosage of 250μg/m2/day for 25 consecutive days. The increase in granulocytes started on day 15 and exceeded 500/cmm by day 19. A platelet count greater than 105 was obtained on day 29. We compared the recovery of granulocytes and platelets in the patient with those in two patients with severe aplastic anemia, who were treated with the same conditioning regimen and received recombinant human granulocyte colony-stimulating factor (rhG-CSF) after BMT. Although recovery of granulocytes by rhGM-CSF administration was similar to that by rhG-CSF, rhGM-CSF seemed to more intensively stimulate platelets recovery than rhG-CSF. He had antibiotics-resistant high fever until the administration of rhGM-CSF was discontinued, suggesting rhGM-CSF itself might be a cause of high fever. No other side effects were observed. These results suggest that rhGM-CSF may be beneficical to hemopoietic recovery after BMT in pediatric patients.
